Pulse Biosciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2022. The filing was signed November 10, 2022. Pulse is a development-stage bioelectric medicine company whose CellFX System uses its Nano-Pulse Stimulation (NPS) technology.
Business context and strategy
In September 2022, the company shifted its focus to developing NPS applications outside dermatology, ended the CellFX Controlled Launch, and stopped active CellFX commercialization while continuing to support existing users. On November 10, 2022, it identified cardiac tissue ablation for atrial fibrillation as its lead application, pursuing catheter and surgical approaches. This remains a development strategy, not an established commercial business.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0.574 million | $0.709 million | $0.574 million |
| Operating loss | $18.025 million | $14.273 million | $49.312 million | $47.604 million |
| Net loss | $18.039 million | $14.282 million | $49.308 million | $48.244 million |
| Operating cash used | — | — | $39.048 million | $41.403 million |
Q3 revenue was zero following the strategy change. Nine-month 2022 revenue included about $0.4 million of non-cash Controlled Launch credits and about $0.3 million from cash sales. Gross margin was negative in Q3: cost of revenue was $8.4 million despite no revenue, principally reflecting a $7.2 million reserve for excess and obsolete inventory. The filing does not present a clear normalized gross margin excluding this reserve.
Nine-month operating expenses were $50.021 million: cost of revenue $10.653 million, research and development $16.744 million, sales and marketing $11.251 million, and general and administrative $11.373 million. Compared with the prior-year period, R&D and G&A declined, but higher cost of revenue—partly due to the inventory reserve—and higher sales and marketing left operating loss $1.708 million larger. Basic and diluted loss per share was $0.49 for Q3 and $1.50 for the nine months.
At September 30, cash and cash equivalents were $69.162 million, versus $28.614 million at December 31, 2021. Current assets were $71.161 million and current liabilities $6.998 million. Total liabilities were $81.381 million, including a $65 million related-party loan from Executive Chairman Robert W. Duggan; stockholders’ equity was $6.189 million. The loan bears 5% interest and matures March 20, 2024. The company had no significant operating cash inflows and reported no off-balance-sheet arrangements.
Financing cash inflows of $79.956 million for the nine months included $65 million from the related-party loan and $14.9 million net proceeds from the June rights offering. Operating cash use was $39.048 million. Management stated that existing cash was expected to fund current operations for at least 12 months from filing, while also saying additional capital would be needed in the future; financing availability and terms are uncertain.
Material changes, outlook, risks and unusual items
- The company recorded a $7.2 million inventory reserve after redirecting away from dermatology; inventory was $0.750 million net at quarter-end, reduced by $7.4 million for excess and obsolete inventory.
- Two workforce reductions in 2022 generated $0.9 million of restructuring charges. Management reported above-normal employee turnover and expected it to continue into early 2023.
- The June rights offering issued 7.317 million shares and warrants at $2.05 per unit, raising $15 million gross. Approximately 56% of the offered shares were purchased by Duggan. At quarter-end, 7.310 million warrants remained outstanding, potentially exercisable for up to $15 million gross proceeds and dilutive to existing holders.
- The company received FDA 510(k) clearance in September to add treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I–III. It nevertheless ceased active dermatology commercialization as it redirected resources to NPS development outside dermatology.
- A securities class action relating to the FDA’s earlier information request on the sebaceous-hyperplasia submission remained pending. The company moved to dismiss; the filing says a possible loss or range cannot be estimated and anticipated a ruling in early 2023.
- Duggan provided personal Side A indemnity coverage for one year after the company chose not to renew its D&O insurance due to high premiums. The company agreed to pay him $1 million at the end of the term; $0.3 million was accrued at September 30. The related-party loan and indemnity arrangement merit attention.
- Key risks include limited revenue, continuing losses and cash burn, reliance on future financing, dilution, the uncertain clinical and regulatory path for cardiac applications, commercial adoption, employee retention, and dependence on a controlling stockholder. Management reported disclosure controls effective and no material change in internal control over financial reporting during the quarter.
Investor verification checklist
- Track cash burn against the stated 12-month runway, financing needs, and the terms or availability of future funding.
- Review the Duggan loan covenants, repayment obligations, accrued interest, and related-party governance; confirm the status of the D&O indemnity coverage and payment.
- Verify the final inventory impact and whether further write-downs or costs arise from ending the Controlled Launch and supporting or retrieving CellFX systems.
- Assess milestones, clinical evidence, regulatory requirements, development spending, and partnership plans for the atrial-fibrillation program.
- Monitor the securities lawsuit, potential exposure, and the court’s ruling, as well as workforce attrition and restructuring effects.
- Consider dilution from outstanding warrants, future fundraising, and the concentration of voting control in Duggan.